Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Journal of Clinical Investigation

Volumn 114, Issue 3, 2004, Pages 379-388

  Borg, Christophe ^a   Terme, Magali ^a   Taïeb, Julien ^a   Ménard, Cédric ^a   Flament, Caroline ^a   Robert, Caroline ^a   Maruyama, Koji ^a,b   Wakasugi, Hiro ^b   Angevin, Eric ^a   Thielemans, Kris ^c   Le Cesne, Axel ^a   Chung Scott, Véronique ^a   Lazar, Vladimir ^a   Tchou, Isabelle ^a   Crépineau, Florent ^a   Lemoine, François ^d   Bernard, Jacky ^e   Fletcher, Jonhantan A ^f   Turhan, Ali ^a   Blay, Jean Yves ^g   Spatz, Alain ^a   Emile, Jean François ^h   Heinrich, Michael C ⁱ   Mécheri, Salah ^j   Tursz, Thomas ^a   Zitvogel, Laurence ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b NATIONAL CANCER CENTER   (Japan)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INSTITUT JEAN GODINOT   (France)

^f HARVARD MEDICAL SCHOOL   (United States)

^g EDOUARD HERRIOT HOSPITAL   (France)

^h HÔPITAL PAUL BROUSSE   (France)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j INSTITUT PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GAMMA INTERFERON; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CLINICAL TRIAL; COCULTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; MUTATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 4043134677     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI21102     Document Type: Article

References (35)

1. Rubin, B.P., et al. 2001. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:8118-8121.
2. Heinrich, M.C., et al. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 31:708-710.
3. Apperley, J.F., et al. 2002. Response to imatinib mesylace in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N. Engl. J. Med. 347:481-487.
4. Buchdunger, E., O'Reilly, T., and Wood, J. 2002. Pharmacology of imatinib (STI571). Eur. J. Cancer. 38:S28-S36.
5. Heinrich, M.C., Blanke, C.D., Druker, B.J., and Corless, C.L. 2002. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20:1692-1703.
6. Demetri, G.D., et al. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:472-480.
7. Heinrich, M.C., et al. 2003. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21:4342-4349.
8. Cohen, M.H., et al. 2002. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer. Res. 8:935-942.
9. Bauer, S., et al. 2003. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother. Pharmacol. 51:261-265.
10. Fernandez, N.C., et al. 1999. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Nat. Med. 5:405-411.
11. Glas, R., et al. 2000. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J. Exp. Med. 191:129-138.
12. Seaman, W.E., Sleisenger, M., Eriksson, E., and Koo, G.C. 1987. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J. Immunol. 138:4539-4544.
13. Colucci, F., and Di Santo, J.P. 2000. The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells. Blood. 95:984-991.
14. Maraskovsky, E., et al. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-1962.
15. Gerosa, F., et al. 2002. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195:327-333.
16. Sun, X., Layton, J.E., Elefanty, A., and Lieschke, G.J. 2001. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL-expressing cells, demonstrating synergy between AG490 and STI571. Blood. 97:2008-2015.
17. Nocka, K., et al. 1990. Molecular bases of dominant: negative and loss of function mutations at the murine c-kit/white spotting locus: W37, Wv, W41 and W. EMBO J. 9:1805-1813.
18. Kitamura, Y., Matsuda, H., and Hatanaka, K. 1979. Clonal nature of mast-cell clusters formed in W/Wv mice after bone marrow transplantation. Nature. 281:154-155.
19. Fernandez, N.C., et al. 2002. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur. Cytokine Netw. 13:17-27.
20. Van Glabbeke, M.M., et al. 2003. Prognostic factors of toxicity and efficacy in patients with gastro-intestinal stromal tumors (GIST) treated with imatinib: A study of the EORTC-STBSG, ISG and AGITG [abstract]. Proc. Am. Soc. Clin. Oncol. 22:3286.
21. Valeytie, L., et al. 2003. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J. Am. Acad. Dermatol. 48:201-206.
22. Buentke, E., et al. 2002. Natural killer and dendritic cell contact in lesional atopic dermatitis skin-Malassezia-influenced cell interaction. J. Invest. Dermatol. 119:850-857.
23. Diefenbach, A., Jensen, E.R., Jamieson, A.M., and Raulet, D.H. 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:165-171.
24. Cerwenka, A., Baron, J.L., and Lanier, L.L. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. U. S. A. 20:11521-11526.
25. Lanier, L.L. 2001. A renaissance for the tumor immunosurveillance hypothesis. Nat. Med. 11:1178-1180.
26. Ruggeri, L., et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2097-2100.
27. Salcedo, M., Momburg, F., Hammerling, G.J., and Ljunggren, H.G. 1994. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells. J. Immunol. 152:1702-1708.
28. Bauer, S., et al. 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 285:727-729.
29. Cosman, D., et al. 2001. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 14:123-133.
30. Groh, V., Wu, J., Yee, C., and Spies, T. 2002. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734-738.
31. Moretta, A. 2002. Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat. Rev. Immunol. 2:957-964.
32. Zitvogel, L. 2002. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med. 195:F9-F14.
33. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 101:3052-3057.
34. Andrews, D.M., Scalzo, A.A., Yokoyama, W.M., Smyth, M.J., and Degli-Esposti, M.A. 2003. Functional interactions between dendritic cells and NK cells during viral infection. Nat. Immunol. 4:175-181.
35. Mantovani, A., Gray, P.A., Van Damme, J., and Sozzani, S. 2000. Macrophage-derived chemokine (MDC). J. Leukoc. Biol. 68:400-404.